TrialJectory, a NYC-based AI-powered technology platform that uses self-reported clinical data to match cancer patients with clinical trials, closed a $2.7m seed financing round.
The round was led by Contour Venture Partners.
The company intends to use the funds to expedite the growth of the platform.
Led by Tzvia Bader, CEO and co-founder, TrialJectory provides an AI-powered technology platform that uses self-reported clinical data to match cancer patients with clinical trials. TrialJectory currently supports trials for breast cancer, colon cancer, bladder cancer, melanoma and myelodysplastic syndromes (MDS; often called preleukemia).
The engine works through mimicking the mind of an oncologist, reading all unstructured treatment descriptions and extracting the data that’s relevant to the patient. The system clusters, classifies and standardizes this information, creating a database that highlights patient attributes attractive to clinical trials. Patients are then matched to clinical trials through self-reported, dynamic questionnaire answers and can filter the trials and share the information with their oncologists to move forward in the process if appropriate. To date, the company has matched thousands of patients for clinical trial enrollment and continues to add new studies to the platform each week.